UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 150

Sortiert nach

Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer

European journal of cancer (1990), 2012-11, Vol.48 (17), p.3140-3149

2012

Volltextzugriff (PDF)

1495 poster INDIVIDUALIZED POSITIONING FOR BREAST RADIOTHERAPY: A COMPREHENSIVE APPROACH FOR OAR PROTECTION

Radiotherapy and oncology, 2011, Vol.99, p.S556-S557

2011

Volltextzugriff (PDF)

The role of systemic therapies in the development of lung sequelae after conformal radiotherapy in breast cancer patients

Cancer research (Chicago, Ill.), 2009-01, Vol.69 (2_Supplement), p.4125

2009

Volltextzugriff (PDF)

5053 POSTER Randomized Phase III Study of First-line Bevacizumab in Combination With Capecitabine or Paclitaxel for HER2-negative LR/MBC: Interim Safety Data

European journal of cancer (1990), 2011, Vol.47, p.S346-S346

2011

Volltextzugriff (PDF)

Abstract P1-10-11: Prone vs. supine positioning for optimizing radiation heart exposure during left breast radiotherapy: A simple clinical tool for prediction

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.P1-P1-10-11

2017

Volltextzugriff (PDF)

Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer

Annals of oncology, 2016-11, Vol.27 (11), p.2046-2052

2016

Volltextzugriff (PDF)

New approaches for the classification of early breast cancer, a heterogeneous disease entity

Memo - Magazine of European medical oncology, 2011-09, Vol.4 (3), p.135-139

Kahán, Z.

2011

Volltextzugriff (PDF)

Safe switch of treatment from the reference product to RGB-02, a proposed biosimilar pegfilgrastim: Analysis of the results of three clinical trials

Annals of oncology, 2018-10, Vol.29, p.viii608-viii609

2018

Volltextzugriff (PDF)

Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses

British journal of cancer, 2014-11, Vol.111 (11), p.2051-2057

2014

Volltextzugriff (PDF)

Inhibition of growth of MX‐1, MCF‐7‐MIII and MDA‐MB‐231 human breast cancer xenografts after administration of a targeted cytotoxic analog of somatostatin, AN‐238

International journal of cancer, 1999-08, Vol.82 (4), p.592-598

1999

Volltextzugriff (PDF)

5058 Bevacizumab (Bev) combined with either capecitabine (X) or weekly paclitaxel (Pac) as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer (LR/MBC): the CECOG phase III TURANDOT trial

European journal of cancer supplements, 2009, Vol.7 (2), p.277-278

2009

Volltextzugriff (PDF)

Expression of growth hormone-releasing hormone (GHRH) messenger ribonucleic acid and the presence of biologically active GHRH in human breast, endometrial, and ovarian cancers

The journal of clinical endocrinology and metabolism, 1999-02, Vol.84 (2), p.582-589

1999

Volltextzugriff (PDF)

Clinical benefit of fulvestrant monotherapy in the multimodal treatment of hormone receptor and HER2 positive advanced breast cancer: a case series

OncoTargets and therapy, 2018-01, Vol.11, p.5459-5463

2018

Volltextzugriff (PDF)

Acute oesophageal toxicity related to paclitaxel-based concurrent chemoradiotherapy for non-small cell lung cancer

Anticancer research, 2013-04, Vol.33 (4), p.1737-1741

2013

Volltextzugriff (PDF)

Administration of a targeted cytotoxic analog of luteinizing hormone-releasing hormone inhibits growth of estrogen-independent MDA-MB-231 human breast cancers in nude mice

Breast cancer research and treatment, 2000-02, Vol.59 (3), p.255-262

2000

Volltextzugriff (PDF)

1800 Final results for overall survival (OS), the primary endpoint of the CECOG TURANDOT prospective randomised trial evaluating bevacizumab-paclitaxel (BEV-PAC) vs BEV-capecitabine (CAP) for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC)

European journal of cancer (1990), 2015-09, Vol.51, p.S263-S264

2015

Volltextzugriff (PDF)

Complete regression of MX‐1 human breast carcinoma xenografts after targeted chemotherapy with a cytotoxic analog of luteinizing hormone–releasing hormone, AN‐207

Cancer, 1999-06, Vol.85 (12), p.2608-2615

1999

Volltextzugriff (PDF)

Synthesis and Biological Evaluation of Cytotoxic Analogs of Somatostatin Containing Doxorubicin or Its Intensely Potent Derivative, 2-pyrrolinodoxorubicin

Proceedings of the National Academy of Sciences - PNAS, 1998-02, Vol.95 (4), p.1794-1799

1998

Volltextzugriff (PDF)

OT2-01-02: First-Line Bevacizumab in Combination with Capecitabine or Paclitaxel for HER2−Negative Locally Recurrent or Metastatic Breast Cancer (LR/MBC): A Randomized Phase III Trial

Cancer research (Chicago, Ill.), 2011-12, Vol.71 (24_Supplement), p.OT2-01-02-OT2-01-02

2011

Volltextzugriff (PDF)

Radiation dose to the nodal regions during prone versus supine breast irradiation

Therapeutics and clinical risk management, 2014-01, Vol.10 (default), p.367-372

2014

Volltextzugriff (PDF)

Antagonists of growth hormone-releasing hormone arrest the growth of MDA-MB-468 estrogen-independent human breast cancers in nude mice

Breast cancer research and treatment, 2000-03, Vol.60 (1), p.71-79

2000

Volltextzugriff (PDF)

The relationship of multifocality and tumor burden with various tumor characteristics and survival in early breast cancer

Neoplasma, 2012, Vol.59 (5), p.566

2012

Volltextzugriff (PDF)

Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial

The lancet oncology, 2013-02, Vol.14 (2), p.125-133

2013

Volltextzugriff (PDF)

Efficacy and safety of RGB-02, a proposed biosimilar pegfilgrastim to prevent chemotherapy-induced neutropenia: Results of a randomized, double-blind, phase III clinical study vs. reference pegfilgrastim in patients with breast cancer receiving docetaxel/doxorubicin

Annals of oncology, 2017-09, Vol.28, p.v555-v555

2017

Volltextzugriff (PDF)

1 – 25 von 150

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(130)
Mit Volltextzugriff
(118)

Publikationsform

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer

1495 poster INDIVIDUALIZED POSITIONING FOR BREAST RADIOTHERAPY: A COMPREHENSIVE APPROACH FOR OAR PROTECTION

The role of systemic therapies in the development of lung sequelae after conformal radiotherapy in breast cancer patients

5053 POSTER Randomized Phase III Study of First-line Bevacizumab in Combination With Capecitabine or Paclitaxel for HER2-negative LR/MBC: Interim Safety Data

Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial—PEARL

Abstract P1-10-11: Prone vs. supine positioning for optimizing radiation heart exposure during left breast radiotherapy: A simple clinical tool for prediction

Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer

New approaches for the classification of early breast cancer, a heterogeneous disease entity

Safe switch of treatment from the reference product to RGB-02, a proposed biosimilar pegfilgrastim: Analysis of the results of three clinical trials

Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses

Inhibition of growth of MX‐1, MCF‐7‐MIII and MDA‐MB‐231 human breast cancer xenografts after administration of a targeted cytotoxic analog of somatostatin, AN‐238

5058 Bevacizumab (Bev) combined with either capecitabine (X) or weekly paclitaxel (Pac) as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer (LR/MBC): the CECOG phase III TURANDOT trial

Expression of growth hormone-releasing hormone (GHRH) messenger ribonucleic acid and the presence of biologically active GHRH in human breast, endometrial, and ovarian cancers

Clinical benefit of fulvestrant monotherapy in the multimodal treatment of hormone receptor and HER2 positive advanced breast cancer: a case series

Acute oesophageal toxicity related to paclitaxel-based concurrent chemoradiotherapy for non-small cell lung cancer

Administration of a targeted cytotoxic analog of luteinizing hormone-releasing hormone inhibits growth of estrogen-independent MDA-MB-231 human breast cancers in nude mice

1800 Final results for overall survival (OS), the primary endpoint of the CECOG TURANDOT prospective randomised trial evaluating bevacizumab-paclitaxel (BEV-PAC) vs BEV-capecitabine (CAP) for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC)

Complete regression of MX‐1 human breast carcinoma xenografts after targeted chemotherapy with a cytotoxic analog of luteinizing hormone–releasing hormone, AN‐207

Synthesis and Biological Evaluation of Cytotoxic Analogs of Somatostatin Containing Doxorubicin or Its Intensely Potent Derivative, 2-pyrrolinodoxorubicin

OT2-01-02: First-Line Bevacizumab in Combination with Capecitabine or Paclitaxel for HER2−Negative Locally Recurrent or Metastatic Breast Cancer (LR/MBC): A Randomized Phase III Trial

Radiation dose to the nodal regions during prone versus supine breast irradiation

Antagonists of growth hormone-releasing hormone arrest the growth of MDA-MB-468 estrogen-independent human breast cancers in nude mice

The relationship of multifocality and tumor burden with various tumor characteristics and survival in early breast cancer

Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial

Efficacy and safety of RGB-02, a proposed biosimilar pegfilgrastim to prevent chemotherapy-induced neutropenia: Results of a randomized, double-blind, phase III clinical study vs. reference pegfilgrastim in patients with breast cancer receiving docetaxel/doxorubicin

Suchergebnisse filtern